Home › Trial NCT01316874
Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)
- Trial IDNCT01316874
- StatusCompleted
- PhasePhase 2/3
- Study typeInterventional
- SponsorEndo USA Inc., a Keenova Therapeutics Company
- Enrollment90
- Start date1993-11
- ConditionsCarcinoma in Situ · Bladder Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.